Can Tazemetostat treat rhabdoid tumors?

Tazemetostat Not currently approved by the U.S. Food and Drug Administration (FDA) for the treatment of rhabdoid tumors (MRT), EZH2 inhibitors have previously been evaluated in a pediatric preclinical trial program tazerestat (also known as EPZ6438), and its activity was observed to be primarily restricted to malignant rhabdoid tumor (MRT) models, with tumors lacking SMARCB1 and therefore lacking the SWI/SNF complex, on EZH2 in adult patients. The suggestion of synthetic lethal dependence is consistent.

In 2020, tazerestat obtained accelerated approval from the FDA for the treatment of metastatic or locally advanced epithelioid sarcoma in adult and adolescent patients aged ≥16 years who are not suitable for complete resection. Tazerestatcan also be used to treat adult patients with follicular lymphoma. Rhabdoid tumors usually occur in infancy and have a poor prognosis, and treatment includes surgery, intensive chemoradiotherapy, and stem cell transplantation with or without transplantation. Several studies have shown that treatment regimens for rhabdomyosarcoma can lead to long-term disease-free status in children with the disease. EPZ011989, a potent EZH2 inhibitor with structural properties and preclinical activity very similar to tametostat, was clinically evaluated, either as a single agent or in combination with drugs used to treat rhabdomyosarcoma and other childhood sarcomas.

The original drug of tazerestat is not yet available in the domestic market and is therefore not included in medical insurance. Tazerestat US version of the original drug, specification200mg*240 tablets, which is marketed overseas, may cost around 200,000 yuan per bottle (the price may fluctuate due to exchange rates), which is very expensive. At present, there are no generic drugs of tazerestat produced and launched. For more drug information and specific prices, please consult the medical consultant of the drug.